Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES014 in Advanced Solid Tumors
NCT05381935Phase 1Withdrawn
- Sponsor
- Elpiscience
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies, Fc Fusion Proteins
01
Overview
Phase 1, open-label trial of ES014 in solid tumor (advanced stage), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Elpiscience. Primary endpoints: Frequency and severity of adverse events of ES014, Dose Limiting Toxicity of ES014 at 28 days and 1 more. Planned start Apr 2023; status: withdrawn.
02
Drugs
ES014
03
Conditions
solid tumor (advanced stage)pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT05381935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381935.